Seroquel Quetiapine Fumarate
Links shared publicly online about this topic
Google Sidewiki entry about Major Depressive Disorder | SEROQUEL XR® (quetiapine fumarate)
google.com — “ http://www.bbc.co.uk/ programmes/b00q3gjj ” View full resource at google.com
Most Recently Shared on October 16, 2010 at 10:16 am By:
Jack Friday - PharmaGossip Health Blog
Just wrote a Sidewiki entry on "Major Depressive Disorder | SEROQUEL XR® (quetiapine fumarate)" http://bit.ly/byjzqf
FDA Panel Recommends Approval of Seroquel for Teens | Psych Central News
psychcentral.com — “Seroquel was voted to be acceptably safe and effective for the treatment of schizophrenia in teenagers, said a U.S. Food and Drug Administration (FDA) panel” View full resource at psychcentral.com
Most Recently Shared on June 10, 2009 at 9:22 pm By:
Psychology Headline: FDA Panel Recommends Approval of Seroquel for Teens @http://is.gd/Y5oN
RxEconsult, LLC - Seroquel (quetiapine) for schizophrenia and bipolar disorder
rxeconsult.com — “RxEconsult, LLC - Seroquel (quetiapine) for schizophrenia and bipolar disorder” View full resource at rxeconsult.com
Most Recently Shared on October 23, 2011 at 1:08 am By:
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." /> Ome Ogbru, PharmD Active Health Library, Doctor, Pharmacist, and PharmD
New article: #Seroquel (quetiapine) for #schizophrenia and #bipolar disorder http://t.co/n46VEiiY #health #medications
Combined Data From Four Large-Scale Studies Demonstrate The Efficacy And Tolerability Of Seroquel In Bipolar Depression
medicalnewstoday.com — “Results presented today at the 162nd American Psychiatric Association (APA) congress in San Francisco, CA, demonstrated the efficacy and tolerability of SEROQUEL® (quetiapine fumarate) for tr” View full resource at medicalnewstoday.com
Most Recently Shared on May 25, 2009 at 2:00 pm By:
psychiatryrounds Psychiatry and Support
Combined Data From Four Large-Scale Studies Demonstrate The Efficacy And Tolerability Of Seroquel In Bipolar Dep.. http://tinyurl.com/pdtdwk
FDA Approves Seroquel XR For Add-On Treatment of Major Depressive Disorder
drugs.com — “Seroquel XR (quetiapine) is used as an adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD). Includes Seroquel XR side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on December 7, 2009 at 11:13 pm By:
FDA Approves Seroquel XR For Add-On Treatment of Major Depressive Disorder - http://bit.ly/8XKlvN
Seroquel (quetiapine): Parkinson's, My Experience w Airline/Sedatives | Dopadoc Parkinson's International
dopadoc.com — “Seroquel (quetiapine) is an antipsychotic medication widely used as an off-label sedative (not FDA approved for this but doctor-prescribed).” View full resource at dopadoc.com
Most Recently Shared on July 13, 2011 at 9:30 pm By:
Marshall Davidson MD Anesthesiologist, Physician, and Doctor
http://t.co/IByef8a Seroquel (quetiapine): Parkinson’s, My Own Experience as a ZOMBIE with Airline Travel and Sedatives
Astrazeneca UK Receives Positive Decision For Seroquel Xl(R) (Quetiapine Prolonged Release) As An Add-On Treatment Of Major Depressive Disorder
medicalnewstoday.com — “AstraZeneca UK is delighted to announce that it has received UK approval for Seroquel XL(R) (quetiapine prolonged release) as an add-on treatment of major depressive episodes in patients with Majo” View full resource at medicalnewstoday.com
Most Recently Shared on October 1, 2010 at 3:05 pm By:
Astrazeneca UK Receives Positive Decision For Seroquel Xl(R) (Quetiapine Prolonged Release) As An Add-On Treatment Of ... http://mnt.to/3KCZ
Seroquel (quetiapine):10Things Everyone with Parkinson's Needs to Know | Dopadoc Parkinson's International
dopadoc.com — “10 thing everyone with Parkinson's needs to be aware about before using this antipsychotic drug off-label (not FDA-approved for this use) as a sleep enhancer.” View full resource at dopadoc.com
Most Recently Shared on July 13, 2011 at 8:22 pm By:
Marshall Davidson MD Anesthesiologist, Physician, and Doctor
http://t.co/LjqJ6On Seroquel (quetiapine): 10 Things Everyone with Parkinson's Ought to Know (before taking it for sleep enhancement)
Seroquel (quetiapine): Off-label for sleep in Parkinson's, My favorite antipsychotic. | Dopadoc Parkinson's International
dopadoc.com — “Seroquel is one of the most commonly prescribed drugs for sleep in Parkinson's. I venture that most docs who write for it are interested in what works.” View full resource at dopadoc.com
Most Recently Shared on July 19, 2011 at 5:30 am By:
Marshall Davidson MD Anesthesiologist, Physician, and Doctor
http://t.co/k9OPHr2 Seroquel On Blogger: Off-label Adventures 1, My Favorite Antipsychotic
Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD) - MPR
empr.com — “Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).” View full resource at empr.com
Most Recently Shared on December 7, 2009 at 4:43 pm By:
MPR News: Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD): Seroquel XR (quetiapine... http://bit.ly/8tfaNR
US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder
medicalnewstoday.com — “Astrazeneca (nyse: azn) announced that the us food and drug administration (fda) has approved once-daily seroquel xr® (quetiapine fumarate) extended release tablets as adjunctive (add-on) tre” View full resource at medicalnewstoday.com
Most Recently Shared on December 5, 2009 at 12:19 pm By:
MNT Depression News Health News
US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder: AstraZeneca (NYSE: AZN) annou.. http://bit.ly/7L8u0I
AstraZeneca launches SEROQUEL XR® for add-on treatment of major depressive disorder
astrazeneca-us.com — “Visit the AstraZeneca U.S. Corporate Web site (www.astrazeneca-us.com) for more information.” View full resource at astrazeneca-us.com
Most Recently Shared on April 16, 2010 at 4:05 pm By:
eyeonfda Pharma and Health Lawyer
AZ launches SEROQUEL XR® (quetiapine fumarate) 4 add-on treatment of major depressive disorder http://ow.ly/1zn8x
AstraZeneca's Seroquel XR receives EC approval as an add-on treatment for major depressive disorder - International
pharmabiz.com — “AstraZeneca announced that the European Commission (EC) has issued a positive decision for the approval of once-daily Seroquel XR (quetiapine fumarate) extended release tablets as an add-on treatment” View full resource at pharmabiz.com
Most Recently Shared on September 3, 2010 at 5:58 am By:
Peter H Brown Doctor and Psychologist
AstraZeneca's Seroquel XR receives EC approval as an add-on treatment of major ... http://bit.ly/dDdf0f #bipolar
AstraZeneca's Seroquel gets EU approval for bipolar recurrence - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “AstraZeneca says that its once-daily Serooquel XR (quetiapine fumarate extended-release tablets) and Seroquel have been approved under the European Mutual Recognition Procedure for the prevention of recurrence of bipolar disorder in patients whose manic,” View full resource at thepharmaletter.com
Most Recently Shared on September 30, 2009 at 3:05 pm By:
RT @ThePharmaLetter: AstraZeneca’s Seroquel gets EU approval for bipolar recurrence http://bit.ly/3cCKZ0 #pharma #depression #bipolar
Medical News: AstraZeneca Settles on Quetiapine Charges for $520M - in Public Health & Policy, Ethics from MedPage Today
medpagetoday.com — “AstraZeneca is paying $520 million to settle charges that it improperly marketed the antipsychotic drug quetiapine (Seroquel) for unapproved indications.” View full resource at medpagetoday.com
Most Recently Shared on April 27, 2010 at 9:42 pm By:
AstraZeneca settles on charges that it improperly marketed Seroquel: http://bit.ly/dBSQDF
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Jack Friday - PharmaGossip
A Big Pharma Insider. Any post may be a joke!
-
Psych Central
Psychology and mental health information and support, since 1995. Pages are maintained by Brandi-Ann Uyemura, Associate Editor.
-
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." />Ome Ogbru, PharmD
Dr. Ome Ogbru is the founder of RxEconsult, which is a social network for healthcare consulting, healthcare jobs, healthcare professionals, healthcare small businesses, life scientists, health information, and more. Members have profiles with details about their services on RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication.
Advertisement
